Industry Insights

From Diagnosis to Treatment: Why Therapeutic Companies Should Have a Laboratory Strategy

LLS founder jon Harol

Jon Harol, Founder, LLS

By: Jon Harol, Founder, Lighthouse Lab Services

One of the most valuable roles of clinical laboratory testing is helping identify patients with an undiagnosed condition who could benefit from treatment.

For pharmaceutical manufacturers and other companies delivering therapeutics, that creates an opportunity: make appropriate testing more accessible and help connect patients with the diagnosis and care they need. This is the promise of “test to treat.” Laboratory testing can uncover an unmet clinical need, inform a treatment decision, and become the starting point for ongoing care.

When that care involves a therapy taken over months or years, the clinical and economic value can extend well beyond the initial test.

 

The opportunity begins with an unmet diagnostic need

Consider a pharmaceutical company with a therapy for a condition that frequently goes undiagnosed. One barrier to reaching patients who could benefit may be that those patients have not yet received an accurate diagnosis. The company could address that gap by partnering with a clinical laboratory or establishing its own clinical testing laboratory. Either approach could make appropriate testing more accessible and create a clearer path from diagnostic evaluation to treatment.

The laboratory establishes the diagnostic evidence. The treating clinician independently determines whether the company’s therapy, another treatment, or no medication is appropriate.

For a manufacturer whose therapy requires ongoing use, identifying an eligible patient can lead to recurring revenue over the course of treatment. That potential changes how the company might evaluate an investment in diagnostic access.

 

The economics extend beyond the initial test

A laboratory typically needs to evaluate the economics of the testing service it provides. A therapeutic company with integrated testing capabilities can also consider the value of the care that follows.

In an appropriately structured program, the company may choose to subsidize testing, offer it at cost, or potentially absorb a loss on the initial test. The business rationale is that subsequent treatment revenue may support the investment in helping patients obtain a diagnosis. In commercial terms, the test can function as a loss leader. In clinical terms, its purpose remains identifying a condition and informing an appropriate care decision.

That distinction matters. Testing should be driven by clinical need, and treatment should follow an independent assessment of what is right for the patient. The financial analysis also needs to go beyond prescription revenue. Companies must account for the full cost of testing, patient outreach, clinical evaluation, treatment delivery, and ongoing support. They must also recognize that some patients will not qualify for treatment, will choose another therapy, or will discontinue care.

The model becomes attractive when better access to diagnosis creates enough value for patients and a sustainable return for the business.

 

Partner with a laboratory or build one

A laboratory partnership can provide access to established testing capabilities, experienced personnel, collection infrastructure, and systems for delivering results. It can be an efficient way to launch a program and understand patient needs before making a larger investment.

Establishing an owned clinical laboratory is another strategic option. For a therapeutic company with sufficient scale and a sustained need for testing, ownership can provide greater control over the testing process, turnaround times, patient experience, and integration with its broader care platform. It can also support follow-up testing when clinically appropriate.

But a clinical laboratory is a substantial operating responsibility. It requires qualified leadership, quality systems, validated testing, regulatory compliance, and ongoing investment.

The decision should depend on the company’s patient population, testing needs, expected scale, capital resources, and ability to operate a high-quality laboratory. A partnership may be the right long-term answer. For another company, building or acquiring a laboratory may make more sense.

 

Laboratory leaders have an opportunity, too

For clinical laboratories, this creates a reason to engage pharmaceutical manufacturers and therapeutic companies earlier in their planning. The conversation can begin with practical questions: Where are patients struggling to obtain a diagnosis? What testing is needed to establish treatment eligibility? How can collection, reporting, and follow-up become easier?

Laboratories that understand those needs can contribute far more than an individual test result. They can help design a reliable diagnostic pathway that supports appropriate treatment decisions.

 

Clinical credibility makes the strategy sustainable

An abnormal result does not automatically justify a prescription. Some patients need additional evaluation, a different intervention, or referral elsewhere. Others need reassurance rather than treatment. A durable test-to-treat strategy must accommodate all of those outcomes. Patients and clinicians need confidence that the testing is reliable and the treatment decision serves the patient’s interests.

I believe more pharmaceutical manufacturers and therapeutic companies should be evaluating laboratory capabilities as part of their strategy—through partnerships, ownership, or a combination of both.

Helping more patients receive an accurate diagnosis can improve access to treatment and create lasting business value. The opportunity starts with finding the patients whose needs are still unmet.

 

Sharing is caring!